Applied Clinical Trials
Institutional overhead remains one of the more contentious areas in clinical grant management. There can be substantial variations in these overhead rates from institution to institution with often times little immediately evident reason for the differences. Institution overhead rates in the United Kingdom seem to reflect that same imprecision.
Institutional overhead remains one of the more contentious areas in clinical grant management. There can be substantial variations in these overhead rates from institution to institution with often times little immediately evident reason for the differences. Institution overhead rates in the United Kingdom seem to reflect that same imprecision.
Unlike virtually any other developed country, the United Kingdom has a single health care provider, the National Health Service (NHS) in England and Wales, with comparable organizations in the other parts of the country. Yet overhead rates vary among the institutions conducting clinical research for commercial organizations.
Each year TTC reports on the relative costs of clinical grants around the world, drawing upon data in the GrantPlan database. Subscribers to this database conduct over 76% of all the commercial clinical trials. According to the data in GrantPlan, average institutional overhead rates in the United Kingdom have averaged around 25% percent over the last five years, an average figure substantially higher than the average institutional overhead rate, 17%, for the other countries in the European Union. Equally noteworthy is the range in institutional overheads across the NHS.
United Kingdom Institutional Overhead Quartiles
The median (and mean) overhead is 25%, with the lowest quartile at 20%. The highest quartile institutions haw overheads beginning at 30%. It appears that the institutions with the highest overheads though are the most willing to negotiate the actual overhead rate paid by the commercial organizations conducting research at that site. These highest quartile hospitals report an official overhead 10 points higher than actually accepted in the final clinical grant.—TTC (for more information, please contact help@ttc-llc.com).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.